Also known as Aloxi
Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV—nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy—and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Source: WikipediaEstimated Total Cost: $732.86 for an average of 21 days supply
Patients are most commonly prescribed palonosetron to treat breast cancer, colorectal cancer, metastatic cancer, and lung cancer.
Critical Interactions
Significant Interactions
Patients taking palonosetron most commonly experience side effects like headache, decreased heart rate, and constipation.